Cancer is an increasing global health problem with a rising 2.3 fold incidence over the last 30 years and, currently, 1 in 5 people will develop cancer in their lifetime. (Zhu et al., 2025; Bray et al., 2024). Due to the variability in effectiveness of traditional treatments, there is a perpetual need to find new or improved therapies. Many patients turn to holistic and plant medicine to improve their quality of life and in hope of increasing the success of traditional chemotherapeutics. (Aycil and Karaca, 2025). Among plant medicines, one of the most common is the use of cannabis. (Martin et al., 2025; Hardy et al., 2025). Many patients use cannabis for palliative care, symptom management or to combat adverse reactions from cancer treatments. (Hardy et al., 2025). There are a few cannabinoid medications currently approved by drug agencies to help manage adverse effects caused by cancer chemotherapy. Synthetic Δ9-THC (dronabinol) and a synthetic analogue, nabilone, are approved for the treatment of nausea, vomiting, and lack of appetite in the United States and most of Europe. (Health Information, 2025). Cannabis-based medicinal products are now officially approved in several countries, including Portugal, Germany, and Italy, for the management of cancer-related symptoms such as pain, nausea and cachexia (Correa and Tucci, 2025).
Some patients, however, hope to battle the tumor itself using cannabis or cannabinoids, and there is some pre-clinical evidence for this intent. In many cancers, there is a dyregulation of phytocannabinoid receptors, including the CB1 and CB2 receptors and GPR55. (Perez-Gomez et al., 2015; Song et al., 2023; Shoeib et al., 2021; Wnorowski et al., 2021). Targeting these receptors and/or altering endocannabinoids has shown promise in pre-clinical trials. (Velasco et al., 2012; Lee et al., 2022; Elbaz et al., 2017; Oh et al., 2013). Some cannabinoids have been found to inhibit tumor progression or induce apoptosis in various cancer cell lines. (Cianchi et al., 2008; Fonseca et al., 2018; Patsos et al., 2010; Sarfaraz et al., 2006). Other studies suggest that cannabinoids exhibit anti-angiogenic properties, disrupt signaling pathways that promote tumor proliferation thus impeding tumor progression, or modulate the immune system to foster an anti-tumor response. (Elbaz et al., 2017; Ramer et al., 2022; Casanova et al., 2003; Kogan et al., 2006; Pisanti et al., 2011; Portella et al., 2003; Ravi et al., 2016; Braile et al., 2021; Dada et al., 2022). There is also evidence that cannabinoids in conjunction with chemotherapeutics can provide improved therapy outcomes in humans, particularly with glioblastoma. (Kyriakou et al., 2021; Bhaskaran et al., 2024). Alternatively, there are studies that suggest that cannabinoids can promote cancer proliferation and could be contraindicated for certain cancers or interfere with existing therapies. (Li et al., 2021; Hasenoehrl et al., 2018; Hu et al., 2011; Martinez-Martinez et al., 2016).
Cannabis use is common among cancer patients and, due to the heterogeneity of cancers and cannabis products being used, there is inconclusive evidence on how cannabis can help or hurt. The aim or our Topic was to highlight recent research on the role of cannabis, cannabinoids, or the endocannabinoid system with regards to treating cancer.
To understand the larger picture of publication frequency and topics for cannabinoids/endocannabinoid system and cancer, Tan et al. conducted a bibliometric analysis of the current literature. They found that from 1995–2024, 3,052 publications were identified using the Web of Science Core Research Topic database spanning manuscripts from 86 countries and 3,362 institutions. The majority of publications on the topic were published after 2021. While most the top 100 publishing institutions were in the United States, cannabis and cancer research was most frequently done in Italy and Spain, with those countries hosting researchers that have published on the topic most frequently. The authors analyzed frequent keywords and revealed several “hotspots” including treatment for cancer-symptoms, (particularly nausea, vomiting, and pain) and the growing evidence for anti-tumor effects of cannabinoid (mostly Δ9-THC and CBD).
An overview of the therapeutic potential of the endocannabinoid system in cancer treatment is presented in a mini-review by Salum et al. The authors explain the endocannabinoid system, how it regulates physiological processes, and how these can potentially contribute to anticancer effects. This is followed by a summary of global impact of cancer, overview of carcinogenesis, and how the endocannabinoid system could interconnect. Specific studies of cannabinoids that suggest anti-tumor effects, including inhibition of tumor growth, cytotoxic effects, and modulation of angiogenesis, are presented. They also caution that some cannabinoids have pro-tumor effects based on context and tumor heterogeneity.
On a more granular level, Ravnik et al. explored possible molecular targets for phytocannabinoids by using an inverse molecular docking approach to search for potential protein targets, many of which are associated with cancer. Cannabinoids demonstrated protein binding similarity in two main categories 1) CBD, CBC, and CBG and 2) Δ9-THC and similar, including CBL-class, presenting opportunities for therapeutic benefits associated with THC but with less psychotropic effects. Two main targets were associated with more favorable docking scores with 12 out of 14 cannabinoids tested: 1) GTPase KRas, a regulator of cell survival, differentiation and growth and which has not been historically receptive to pharmacotherapy attempts and 2) hematopoietic cell kinases, which are involved in cellular homeostasis, innate immune response, and have been linked to the onset of various cancers.
Another angle for therapeutic development of cannabinoids was approached by Vigano et al. by reviewing the evidence of cannabinoids’ ability to modulate the pharmacodynamics of immunotherapy checkpoint inhibitors. They detail the concept of immune checkpoints for inhibitor immunotherapy during cancer treatment, receptors associated with the endocannabinoid system and their interaction with the immune system. In discussing specific studies, the authors highlight that cannabinoids have been shown to inhibit T-cell mediated response in murine models. Observational studies found cannabinoid use leads to decreased time for tumor progression but minimized adverse events associated with immune therapy. The authors caution that studies to date are not uniform and need more statistical power.
Two in vitro studies delved into the mechanisms by which cannabinoids could affect cancer cells. Tong et al. conducted an in vitro study with two lines of ovarian cancer cells (SKOV3 and A2780) assessing the cytotoxicity of CBD, Δ9-THC, and both combined. The authors demonstrated cytotoxicity of both compounds in cancer cells lines, without harming the non-tumor IOSE cells, with ratio- and concentration-dependent synergy. The combination more effectively inhibited proliferation, impaired cellular migration, and induced apoptosis by down-regulating phosphorylation of and thus suppressing the PI3L/AKT/mTOR signaling pathway while restoring the tumor suppression function of PTEN.
Chen at al. explored the in vitro cytotoxic effects of natural cannabinoids and their synthetic derivatives in human ovarian cancer cells. CBD and CBN exhibited the greatest cytotoxicity with CBD showing more antiproliferative effects. The authors created fifty-six synthetic analogs of CBD and two of those showed enhanced cytotoxic effects. Both analogs contained an added piperazine moiety. At IC50 concentrations, these two analogs did not show apoptotic effects but did show enhanced iron levels for ferroptosis, although mechanism of cell death still needs to be confirmed. They assessed these analogs for synergistic effects with cisplatin, and one analog enhanced the antiproliferative effects of cisplatin. This is of particular interest in developing medications for chemotherapy-resistant ovarian cancers.
In conclusion, it is evident that research about cannabinoids and the endocannabinoid affecting cancer treatment is on the rise. In vitro studies continue to show promise for cannabinoids to enhance treatments. Targets are expanding beyond direct cytotoxic effects to include synergistic combinations with established therapies and the exploration of novel molecular targets, supporting an integrative therapeutic role now being explored in multiple clinical trials. Continued research on how cannabinoids can assist with anti-tumor treatment both by enhancing anti-tumor treatments and improving patients’ quality of life is still essential. Encouraging evidence is steadily growing, providing strong momentum toward clinical applications.
Statements
Author contributions
LF: Writing – original draft, Writing – review and editing, Conceptualization. WR-K: Writing – review and editing, Conceptualization. BF: Writing – review and editing, Conceptualization.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Aycil I. Karaca A. (2025). Assessment of cancer patients' attitudes toward holistic complementary and alternative medicine and factors influencing these attitudes. Altern. Ther. Health Med.
2
Bhaskaran D. Savage J. Patel A. Collinson F. Mant R. Boele F. et al (2024). A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer24 (1), 83. 10.1186/s12885-023-11792-4
3
Braile M. Marcella S. Marone G. Galdiero M. R. Varricchi G. Loffredo S. (2021). The interplay between the immune and the endocannabinoid systems in cancer. Cells10 (6), 1282. 10.3390/cells10061282
4
Bray F. Laversanne M. Sung H. Ferlay J. Siegel R. L. Soerjomataram I. et al (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.74 (3), 229–263. 10.3322/caac.21834
5
Casanova M. L. Blazquez C. Martinez-Palacio J. Villanueva C. Fernández-Aceñero M. J. Huffman J. W. et al (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest111 (1), 43–50. 10.1172/JCI16116
6
Cianchi F. Papucci L. Schiavone N. Lulli M. Magnelli L. Vinci M. C. et al (2008). Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin. Cancer Res.14 (23), 7691–7700. 10.1158/1078-0432.CCR-08-0799
7
Correa L. G. Tucci A. M. (2025). Impact of medical cannabis on the quality of life of cancer patients: a critical review. J. Integr. Complement. Med. 10.1177/27683605251377417
8
Dada S. Ellis S. L. S. Wood C. Nohara L. L. Dreier C. Garcia N. H. et al (2022). Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours. Front. Immunol.13, 982082. 10.3389/fimmu.2022.982082
9
Elbaz M. Ahirwar D. Ravi J. Nasser M. W. Ganju R. K. (2017). Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer. Oncotarget8 (18), 29668–29678. 10.18632/oncotarget.9408
10
Fonseca B. M. Correia-da-Silva G. Teixeira N. A. (2018). Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis. J. Physiol. Biochem.74 (2), 261–272. 10.1007/s13105-018-0611-7
11
Hardy J. R. Greer R. M. Pelecanos A. M. Huggett G. E. Kearney A. M. Gurgenci T. H. et al (2025). Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol. Support Care Cancer33 (8), 715. 10.1007/s00520-025-09763-5
12
Hasenoehrl C. Feuersinger D. Sturm E. M. Bärnthaler T. Heitzer E. Graf R. et al (2018). G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int. J. Cancer142 (1), 121–132. 10.1002/ijc.31030
13
Health Information (2025). Cannabis (Marijuana) and Cannabinoids: What You Need To Know. Natl. Cent. Compliment. Integr. Health. Available online at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know (Accessed November 14, 2025).
14
Hu G. Ren G. Shi Y. (2011). The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene30 (2), 139–141. 10.1038/onc.2010.502
15
Kogan N. M. Blazquez C. Alvarez L. Gallily R. Schlesinger M. Guzmán M. et al (2006). A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol. Pharmacol.70 (1), 51–59. 10.1124/mol.105.021089
16
Kyriakou I. Yarandi N. Polycarpou E. (2021). Efficacy of cannabinoids against glioblastoma multiforme: a systematic review. Phytomedicine88, 153533. 10.1016/j.phymed.2021.153533
17
Lee H. S. Tamia G. Song H. J. Amarakoon D. Wei C. I. Lee S. H. (2022). Cannabidiol exerts anti-proliferative activity via a cannabinoid receptor 2-dependent mechanism in human colorectal cancer cells. Int. Immunopharmacol.108, 108865. 10.1016/j.intimp.2022.108865
18
Li L. T. Zhao F. F. Jia Z. M. Qi L. Q. Zhang X. Z. Zhang L. et al (2021). Cannabinoid receptors promote chronic intermittent hypoxia-induced breast cancer metastasis via IGF-1R/AKT/GSK-3beta. Mol. Ther. Oncolytics23, 220–230. 10.1016/j.omto.2021.09.007
19
Martin C. D. Rivard C. Kasza K. Case A. A. Hansen E. Goniewicz M. L. et al (2025). Trends in cannabis use among those with and without a cancer diagnosis according to state-level cannabis policy: findings from the PATH study, waves 1-5 (2013-2019). Support Care Cancer33 (7), 560. 10.1007/s00520-025-09617-0
20
Martinez-Martinez E. Martin-Ruiz A. Martin P. Calvo V. Provencio M. Garcia J. M. (2016). CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3beta signaling pathway. Oncotarget7 (42), 68781–68791. 10.18632/oncotarget.11968
21
Oh J. H. Lee J. Y. Baeg M. K. Han K. H. Choi M. G. Park J. M. (2013). Antineoplastic effect of WIN 55,212-2, a cannabinoid agonist, in a murine xenograft model of gastric cancer. Chemotherapy59 (3), 200–206. 10.1159/000355666
22
Patsos H. A. Greenhough A. Hicks D. J. Al Kharusi M. Collard T. J. Lane J. D. et al (2010). The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Int. J. Oncol.37 (1), 187–193. 10.3892/ijo_00000666
23
Perez-Gomez E. Andradas C. Blasco-Benito S. Caffarel M. M. García-Taboada E. Villa-Morales M. et al (2015). Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. J. Natl. Cancer Inst.107 (6), djv077. 10.1093/jnci/djv077
24
Pisanti S. Picardi P. Prota L. Proto M. C. Laezza C. McGuire P. G. et al (2011). Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood117 (20), 5541–5550. 10.1182/blood-2010-09-307355
25
Portella G. Laezza C. Laccetti P. De Petrocellis L. Di Marzo V. Bifulco M. (2003). Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J.17 (12), 1771–1773. 10.1096/fj.02-1129fje
26
Ramer R. Wendt F. Wittig F. Schäfer M. Boeckmann L. Emmert S. et al (2022). Impact of cannabinoid compounds on skin cancer. Cancers (Basel)14 (7), 1769. 10.3390/cancers14071769
27
Ravi J. Elbaz M. Wani N. A. Nasser M. W. Ganju R. K. (2016). Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. Mol. Carcinog.55 (12), 2063–2076. 10.1002/mc.22451
28
Sarfaraz S. Afaq F. Adhami V. M. Malik A. Mukhtar H. (2006). Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J. Biol. Chem.281 (51), 39480–39491. 10.1074/jbc.M603495200
29
Shoeib A. M. Yarbrough A. L. Ford B. M. Franks L. N. Urbaniak A. Hensley L. L. et al (2021). Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sci.285, 119993. 10.1016/j.lfs.2021.119993
30
Song Q. Zhang W. Shi D. Zhang Z. Zhao Q. Wang M. et al (2023). Overexpression of cannabinoid receptor 2 is associated with human breast cancer proliferation, apoptosis, chemosensitivity and prognosis via the PI3K/Akt/mTOR signaling pathway. Cancer Med.12 (12), 13538–13550. 10.1002/cam4.6037
31
Velasco G. Sanchez C. Guzman M. (2012). Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer12 (6), 436–444. 10.1038/nrc3247
32
Wnorowski A. Wojcik J. Maj M. (2021). Gene expression data mining reveals the involvement of GPR55 and its endogenous ligands in immune response, cancer, and differentiation. Int. J. Mol. Sci.22 (24). 10.3390/ijms222413328
33
Zhu L. Zhu J. Wang Q. Sun X. Yuan Y. Ding S. et al (2025). Global, regional, and national burden of 34 cancer groups across 204 countries and territories, 1990-2021, and projections to 2050: a systematic analysis of the global Burden of Disease Study 2021. Front. Oncol.15, 1660125. 10.3389/fonc.2025.1660125
Summary
Keywords
anti-tumor mechanisms, cancer therapy, cannabinoids, chemotherapy synergy, endocannabinoid system, palliative care
Citation
Franks LN, Raup-Konsavage W and Fonseca BM (2026) Editorial: The role of cannabinoids and the endocannabinoid system in anti-cancer therapy. Front. Pharmacol. 17:1754350. doi: 10.3389/fphar.2026.1754350
Received
25 November 2025
Revised
15 January 2026
Accepted
16 January 2026
Published
27 January 2026
Volume
17 - 2026
Edited and reviewed by
Massimo Nabissi, University of Camerino, Italy
Updates
Copyright
© 2026 Franks, Raup-Konsavage and Fonseca.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lirit N. Franks, lirit.franks@hsc.utah.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.